Key points are not available for this paper at this time.
Abstract Introduction p: 0.976), with an average recurrence of 31.36±32.47 months (p: 0.894). Metastases (2.3%) occurred in 1 SCC patient after 12 months, and tumor expansion (2.3%) occurred in 1 SGC patient. Conclusion : There was no difference in the incidence of tumor recurrence, metastasis, and expansion based on tumor type and location. However, there was a significant difference in the type of management taken against the tumor expansion. Follow-up must be done for at least three years after therapy.
Priani et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: